- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05136885
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.
Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.
If a participant is randomized to Regimen E SLS-005 - Trehalose, the participant will complete a screening visit to assess additional Regimen E eligibility criteria. Once Regimen E eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active SLS-005 or matching placebo.
Regimen E will enroll by invitation, as participants may not choose to enroll in Regimen E. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen E.
For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Healey Center for ALS at Mass General
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).
Exclusion Criteria:
The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
- Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus
- Master Protocol screening glucose >140 mg/dl
- Prior treatment with IV trehalose or known hypersensitivity to trehalose
- Current use of oral trehalose (see prohibited medication Section 5.9)
- Inability for participant to return to site for weekly drug administration, until approved for home infusions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SLS-005
SLS-005 is administered via infusion once weekly for 24 weeks.
|
Administration: Infusion Dose: 0.75 g/kg weekly
|
Placebo Comparator: Matching Placebo
Matching placebo is administered via infusion once weekly for 24 weeks.
|
Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Progression
Time Frame: 24 Weeks
|
Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R).
Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
|
24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory Function
Time Frame: 24 Weeks
|
Change in respiratory function over time as measured by Slow Vital Capacity (SVC).
|
24 Weeks
|
Muscle Strength
Time Frame: 24 Weeks
|
Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).
|
24 Weeks
|
Survival
Time Frame: 24 Weeks
|
Comparison of rate of occurrence between groups.
|
24 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Merit Cudkowicz, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019P003518E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on SLS-005
-
Seelos Therapeutics, Inc.WithdrawnAlzheimer's DiseaseAustralia
-
Seelos Therapeutics, Inc.TerminatedSpinocerebellar Ataxia Type 3United States, Spain, Korea, Republic of, Australia, United Kingdom, Brazil, Germany, Portugal
-
Merit E. Cudkowicz, MDMassachusetts General HospitalRecruiting
-
Seelos Therapeutics, Inc.Massachusetts General Hospital; National Institute of Neurological Disorders... and other collaboratorsNo longer available
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Eleven BiotherapeuticsCompleted
-
101 TherapeuticsActive, not recruitingVirus Diseases | COVID-19 | Infectious Disease | Glucocorticoids ToxicityIndia
-
AbbVieTerminated
-
BJ Bioscience, Inc.Active, not recruitingAdvanced Solid Tumor or LymphomaUnited States
-
Xenon Pharmaceuticals Inc.Completed